MaaT Pharma

• Initial Public Offering on the regulated market of Euronext Paris of 2,333,333 shares at a price of €13.50 per share, raising total gross proceeds of €31.5 million, which can increase to €36.2 million in case the over-allotment option is exercised in full
• The transaction represents the biggest Life Sciences IPO on Euronext Paris in 2021YTD 
• Kempen & Co extensively marketed the transaction towards a large group of domestic as well as international specialist and generalist institutional investors in the various marketing phases of the IPO
• MaaT Pharma becomes the first publicly traded company developing microbiome-based drugs in continental Europe
• The proceeds will primarily be used to fund the Phase III clinical trial evaluating lead product candidate MaaT013 for the treatment of graft-versus-host disease (GvHD), the initiation of a Phase II/III of MaaT033, and preparatory work for the Phase I of MaaT03X as well as the manufacturing scale-up of MaaT013, MaaT033 and MaaT03X
• MaaT Pharma’s IPO marks the ninth Equity Capital Markets transaction on the regulated market of Euronext Paris in which Kempen & Co acted as an underwriter since 2015
• Trading of MaaT Pharma’s shares on the regulated market of Euronext Paris under the symbol “MAAT” started on 8 November 2021
• In 2021 year to date, Kempen & Co has executed 21 Equity Capital Markets transactions, totalling USD 2.3 billion, for European life sciences companies listed across Europe and in the US 

MaaT Pharma is a clinical-stage company with a well-established approach to restoring patient-microbiome symbiosis to improve survival outcomes in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients and completed a Phase II clinical trial. Their discovery and analysis platform, gutPrint®, supports the development and expansion of the company’s pipeline by determining novel disease targets, evaluating drug candidates and identifying biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to establish the utilization of microbiome treatment integration into clinical practice. The company is headquartered in Lyon, France. 

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Co-Manager in the USD 460 million Capital Increase by Ascendis Pharma 
• Joint Bookrunner in the SEK 324 million Capital Increase by Calliditas Therapeutics
• Joint Global Coordinator & Joint Bookrunner in the SEK 380 million Capital Increase by Xbrane Biopharma
• Joint Global Coordinator in the €34.1m Capital Increase by Transgene
• Joint Global Coordinator & Joint Bookrunner in the SEK 141 million Capital Increase by Immunicum
• Lead Manager in the USD 63.8 million Nasdaq Initial Public Offering by Molecular Partners
• Joint Bookrunner in the SEK 301 million Capital Increase by Q-linea
• Co-Manager in the USD 176 million Nasdaq Initial Public Offering by Achilles Therapeutics 
• Joint Bookrunner in the €30.0 million Capital Increase by GenSight Biologics
• Lead Manager in the USD 101 million Nasdaq Initial Public Offering by LAVA Therapeutics
• Joint Bookrunner in the USD 120 million Nasdaq Initial Public Offering by European Biotech Acquisition Corp (EBAC)
• Joint Bookrunner in the SEK 1.11 billion Capital Increase by Oncopeptides
• Joint Global Coordinator and Joint Bookrunner in the SEK 962 million Capital Increase by BioInvent
• Co-Manager in the USD 115 million US Public Offering by Y-mAbs Therapeutics
• Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
• Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
• Co-Manager in the USD 190 million Nasdaq Initial Public Offering by Pharvaris
• Bookrunner in the USD 518 million US Public Offering by CureVac
• Lead Manager in the USD 120 million US Public Offering by Merus 
• Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
• Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
• Financial Adviser to DCprime in its merger with Immunicum 
• Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics